The FLT3-ITD mutation may drive the expression of SPNS3, and SPNS3 could become an alternative therapeutic target to help overcome the relatively poor prognosis of patients with FLT3-ITD-positive AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.